Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Does anyone know what percentage Blackrock owned prior to the filing of form 13g/a?
So are they basically the ones that have been suppressing the share price?
-RG
I didn't see an article dated for 2019- can you post a link?
He's commented on ANIP every year at the end of January since 2015. If you're referencing the 2018 article, we'll probably see more around Jan 20.
Here's 2018:
Finally, ANI Pharmaceuticals [ANIP] is a specialty generic and branded pharmaceutical company. It was trading in 2013 at $6 a share. It is now at $70, when shares of many other generic-drug companies have all but collapsed. Ebitda went from nothing in 2013 to an estimated $100 million this year. The stock trades for about eight times enterprise value to Ebitda, whereas other generic-drug companies have been acquired for 12 to 15 times Ebitda. This company potentially could become an acquisition candidate. In a year or two, ANI will launch a corticotropin product that competes in a $1.2 billion market. The company has said the product could yield $200 million of Ebitda.
What is it used to treat?
Schafer: It is a drug for treatment of infantile spasms and multiple sclerosis. ANI bought its product from Merck in 2016 for $75 million. It had already been approved by the Food and Drug Administration, and ANI will have to prove to the FDA that it can manufacture the same product that was on the market in the 1990s. ANI’s other new product is Vancocin, which addresses a $450 million market. The stock could be $120 in a year without the corticotropin, and $200 after the company launches it. ANI isn’t highly levered, and it has the ability to make acquisitions, while its competition doesn’t. For example, last year, it paid AstraZeneca [AZN] $46 million for a variety of products that had $19 million of sales, 80% gross profit margins, and no incremental costs. So it paid $46 million for $16 million of Ebitda.
Meryl Witmer: Where is the company domiciled?
Schafer: It is based in Baudette, Minn., and manufactures there. That’s it from me.
Here's 2017:
I am also re-recommending ANI Pharmaceuticals [ANIP], a producer of generic drugs, which I discussed at prior Roundtables. The stock rose 30% in 2016. This was in an environment where Valeant Pharmaceuticals International [VRX] fell 80% and Teva Pharmaceutical Industries [TEVA] fell 50%. ANI is on course to achieve its short-term goal of generating $100 million of Ebitda. The company has only 11.5 million shares and is trading for $60 a share.
Oscar Schafer: “Interxion gives me the opportunity to benefit from broad secular trends without needing to pick individual technology winners and losers. Another thing I like is the company’s ability to reinvest profits at high rates of return.
Oscar Schafer: “Interxion gives me the opportunity to benefit from broad secular trends without needing to pick individual technology winners and losers. Another thing I like is the company’s ability to reinvest profits at high rates of return. Photo: Jenna Bascom
The most interesting thing about ANI, in addition to its own product pipeline, is its optionality on a generic corticotropin product. A rival product, Acthar, is manufactured by Mallinckrodt [MNK] and sells for $28,000 a vial. ANI bought an NDA [new drug application] from Merck [MRK] for a similar product, and I hope it soon will file an sNDA [supplemental new drug application] to compete in this $1.5 billion market. The first 12 months ANI’s generic version is on the market, and I’m not sure when that will be, ANI should generate $200 million in Ebitda.
Witmer: What does Acthar treat?
Schafer: It is used to treat infantile spasms and multiple sclerosis. That’s it for me.
-RG
Short interest down 3/4 percent for the first half of December compared to the latter half of November.
RG
Hedge funds are taking advantage of the news on price fixing on generics maybe- the current count is at 47 companies I believe. It's not just Anip but the whole sector. Stay put. I can't recall who mentioned it before but it's new extremes- higher highs, lower lows. Let them play with the dead mouse a bit more.
RG
Hit a new intraday low for the year- lovely...6 months ago we were at the high, a year ago we were at the previous high...the share price has stagnated since August...what is with this bloody stock!
-Huff-
-RG
Thanks for the info Jadite!
Hopefully we'll have a repeat of the quick change north like we had last December.
RG
They need to start purchasing some shares- I would love to see his confidence carried behind that act.
RG
I agree- today's volume and our approach to the year low is both frustrating and worrisome. Any thoughts from the group?
RG
Good volume and direction- I can't imagine it's because they're presenting on October 3 but the timing is right on for that announcement- can anyone school me on the significance the market sees in it? They've presented at conferences in the past and I can't recall one that's caused any sort of reaction. Or is the cat just done playing with mouse and the timing is coincidental?
I hope those in Geron played it well.
GLTA
-RG
Shorts floated dropped a little more than 1%. With this we may see some lift in the near future.
-RG
The acquisition also probably explains all of the insider selling that was taking place earlier this year. Divesting from ANI, investing in a company that is later acquired by ANI.
I was expecting a drop but this is a bit overkill. Short interest rose this past month, nearing 13%. I think we'll have another frustrating September leading into a hopeful October.
RG
The institutional holdings data? I don't see anything that is overtly worrisome or motivating, but I do worry about the static nature the share price has hit. I would be disappointed, but not totally surprised, if we suddenly drop a few bucks given the increased short interest. Hopefully this quarters earnings report will be consistent with positive news but differ in the market reaction when compared to what we've seen in the past.
JMHO
RG
Thanks Jadite.
A question for the group: As we head into earning this go around, any opinions on the rise in shorts over the past quarter compared to the past two quarters having been consistently below 10%. From what I recall, the price tended to fall leading up to the report, then normalize on the good news and remain pretty static. Given the rise in short interest is tracking with a rise in the share price, any predictions on whether the pattern will remain or change heading into earnings? Am I trying to correlate something that doesn't correlate?
The volume of shorts still isn't enough for me to worry, but I am curious as to why it's increased recently.
RG
Thanks Jeff!
It's dated today but it's been ramping up over the past few weeks? We've also had positive articles written in the past that have done very little to the share price (either up or down). I have noticed, however, the day or two after a major holiday the pps tends to climb- especially high over long/extended weekends.
The volume, to me, is still too low for the bomb we're all waiting for (as of writing this it's at 220k). Hopefully this triggers a cascade of good PR- ANI (imho) isn't doing the best at putting their name out there in that respect.
Just my take on this rollercoaster ride
RG
The news was worthy enough to be in a seeking alpha article today but trading is business as usual...
Seeking Alpha
I'll save you a click:
In other news
ANI Pharmaceuticals (NASDAQ:ANIP) is buying generic products (five approved generic ANDAs and one pipeline product (Erythromycin IR tablets), as well as a license, supply and distribution deal for another pipeline product, Diclofenac-Misoprostol DR tablets, with a pending ANDA) and other assets from Amneal Pharmaceuticals and Impax Laboratories (NASDAQ:IPXL) for cash. These assets are part of an FTC-mandated divestiture required for the proposed business combination of the latter two.
RG
Short interest as of 04/13/18: 684.95K
I really don't understand how we can be down from our high in December. Even with positive news, any gains are just going to normalize our losses over the past quarter...
RG
I think the first round was at $6 and some change, then 33? Now $57. Hopefully this changes things up tomorrow.
RG
I asked them about that merger/takeover, they said they don't respond to rumors... In regards to Libigel, they told me that all discussions on the subject can be reviewed on their website and their public statements. I asked for links directly to those discussions given their overt silence on the matter and they never responded.
RG
Very active positions as well microbiologists/chemist and regulatory affairs...good sign.
RG
I emailed them back in March wanting info on Libigel- they said all of the info is available on their website.
I emailed them back and requested links directly citing the product- they never emailed back.
I emailed them recently- twice, about insider selling- they didn't respond.
RG
I don't think the selling influenced the stock price to fall as it did recently, it was slowly falling before the sales.
The volume is extremely low- I agree- and given that, the share price is easily malleable, but the pattern is consistent for what it's done for a long while- slowly drops over weeks to months then jump a few dollars- wash rinse repeat.
The most recent sales were in the 500 share range, all executed close together. The sales prior to this were 1.5k-2k at a time. The directors have never sold in this pattern before, their selling previously seen as outliers...I think the sales were a part of something calculated, something directed by rules that we may never be privy to, something linked to a clear directive towards something else (altering % of shares owned to qualify for something else, or divesting into another entity?) but I'd guess the selling that occurred in March may be correlated with taxes but I would not be surprised that those actions are connected to the reason they needed to issue the ct order. JMHO
-RG
Issued a confidential treatment order...Too many things happening with too much silence behind them...but to me, this is screaming buyout.
-RG
I spoke with Art shortly after the merger and was informed that their interest in Libigel would be to sell it or partner on it. It's frustrating to be kept in the dark as long as we've been. I would remind everyone to contact investor relations with these, and anyother questions you may have as well, and post information when obtained. If they don't respond, send it to them again. At best it may put enough pressure to give an answer, at its worst, at least the questions were asked, timestamped and remained unreplied for use on any future litigation.
Today was rough and a reminder that loss and gain are brothers twain.
-RG
I think it's the closing of open positions.
I emailed PR last week, still waiting for a response, not going to hold my breath, but I would suggest everyone contact them with any and ALL questions, maybe if they hear from more than just a handful of us they'll slip up and actually answer one of our questions!
RG
"Asset grab for another deal." Nail on the head. My thoughts (for what they're worth), are leaning more towards a quid pro quo arrangement between a parent company interested in buying ANIP, and aquiring other NDA's they may have otherwise been unable to obtain themselves, but still desire, as a part of a larger deal we're still unfamiliar with.
-RG
Omg that was awesome!
I'll second that.
I actually spoke to Mr. P several weeks ago- I was frustrated at the clear manipulation of the stock and asked him about it- he said that he's heard the fodder on the message boards, all he could tell me is that institutional investors are who he is focused on, not retail and that anything below a pps of $30 is a steal. He didn't go into detail about libigel- he says it's still on the table, but he's currently focused on other projects at the moment.
He's a good guy- if anything, I'm staying in it just because of him.
GLTA and thanks JTFM- you need to give us your paypal/popmoney username or email so we can all buy you a beer.
-RG
Zacks upgraded us to a buy- I honestly have no idea what this means as Zacks is always up and down with their opinions- I have a sinking feeling we're gonna drop down as we did last time Zacks upgraded us- this would be beyond all reason given the recent quarterly results.
I, as well as a majority of this group, agree that patience will be a virtue with this stock.
I'm surprised no one is really discussing jadite's post that Mangano bought some more recently- I think 2k shares
-RG
Strong buy through zacks announced today
-RG
Presentation confirmed:
ANI Pharmaceuticals to Present at 26th Annual ROTH Conference
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)Intraday Stock Chart
Today : Thursday 6 March 2014BAUDETTE, Minn., March 6, 2014 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that its President and Chief Executive Officer, Arthur S. Przybyl, is scheduled to present at the 26th Annual ROTH Conference at the Ritz-Carlton at Laguna Niguel, California onMonday, March 10, 2014at 11:30 a.m. Pacific Time. Charlotte C. Arnold, Vice President and Chief Financial Officer, will also be in attendance and representing ANI. Mr. Przybyl's presentation will be webcast live at http://wsw.com/webcast/roth28/anip, and archived and available through the link through June 8, 2014.
new article out
Wall St. Cheat Sheet
ANI Pharmaceuticals Continues Big Run
Tom Meyer | More Articles
March 05, 2014
Source: Thinkstock
Investors have seen the biotechnology momentum continue during Wednesday’s trading session with several biotechnology stocks producing significant gains. While secondary offerings can often be seen in a negative light because of the dilutive effect, they can occasionally be taken in a positive way if a company can get a favorable deal. ANI Pharmaceuticals (NASDAQ:ANIP) is a shining example of the right way to price a secondary offering.
ANI Pharmaceuticals is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The company’s mission is to develop, manufacture, and market niche generic pharmaceuticals, focusing on opportunities in pain management, anti-cancer, women’s health, and complex formulations including extended release and combination products.
Shares of ANI Pharmaceuticals have had quite a run over the past few weeks. The big run started on February 18 when ANI announced extremely strong fourth-quarter earnings. The highlights included:
Fourth quarter revenue totaled $10.5 million, a year-over-year increase of 98 percent. The increase was due primarily to a 170 percent increase in net prescription sales.
Fourth quarter net income from continuing operations was $3.4 million, compared to a loss of $3.99 million during the same period a year ago.
In the weeks following the announcement, shares of ANI Pharmaceuticals have run from $21.47 all the way up to about $37 per share. Today’s big move is the result of a secondary offering at a favorable price for investors. Typically, when a biotechnology stock has a big move and decides to offer shares, the price can be fairly low compared to where the stock is trading. Not in this case. ANI Pharmaceuticals priced a firm commitment of about 1.4 million shares at a price of $31 per share. Before any fees are paid, the company will net $43.5 million.
This impressive run is also likely due to several positive developments that occurred in 2013. One of the most important moves came in December 2013 when ANI Pharmaceuticals acquired 31 generic drug products from Teva Pharmaceuticals. ANI agreed to pay $12.5 million plus a percentage of future gross profits in exchange for the rights to the generic drugs. The acquisition included:
20 solid-oral immediate release products
4 extended release products
7 liquid products
IMS Health estimates that the market for the acquired products is approximately $860 million.
Going forward, investors are likely looking at a continuing growth story. Since 2010, ANI Pharmaceuticals has grown its revenue from about $8 million to $30 million. The company has also managed to do this while decreasing its cost of sales as a percentage of net revenues (excluding depreciation and amortization.)
2010 — 39 percent cost of sales as a percentage of net revenues
2011 — 42 percent cost of sales as a percentage of net revenues
2012 — 43 percent cost of sales as a percentage of net revenues
2013 — 33 percent cost of sales as a percentage of net revenues
Whether that trend will continue is up for debate, but it is certainly encouraging, and based on the investor appetite for today’s secondary offer, the momentum appears to be firmly in ANI’s corner.
Follow Tom on Twitter @TommyMeyer82
More From Wall St. Cheat Sheet:
Jtfm penny for your thoughts
Priced @ $31.
ANI Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock
PrintAlert
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)Intraday Stock Chart
Today : Wednesday 5 March 2014BAUDETTE, Minn., March 5, 2014 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (the "Company") (NASDAQ: ANIP) today announced that it has priced a firm commitment underwritten public offering of 1,402,525 shares of the Company's common stock at a purchase price to the public of $31.00 per share, resulting in net proceeds to the Company of $43.5 million (before estimated offering expenses payable by us). Oppenheimer & Co. Inc. and Roth CapitalPartners are acting as joint book-running managers for the offering. The offering is expected to close on or about March 10, 2014, subject to customary closing conditions. The Company also granted the underwriters a 30-day option to purchase up to an additional 210,378 shares. The Company expects to use the netproceeds of the offering to research, develop, commercialize and expand its drug products, to acquire complementary businesses and technologies and for working capital and general corporate purposes.The securities described above are being offered by the Company pursuant to a "shelf" registration statement previously filed with and declared effective by the Securities and Exchange Commission (SEC) onJune 17, 2011. Aprospectus supplement and an accompanying prospectus will be filed with the SEC in connection with the offering. Once filed, the prospectus supplement and accompanying prospectus may be obtained by sending a request to Oppenheimer & Co. Inc., Attention: Syndicate Prospectus Department, 85 Broad Street, 26th Floor, New York, NY10004, or by telephone at (212) 667-8563, or by email at EquityProspectus@opco.com, or from Roth Capital Partners, LLC, Attention:Equity Capital Markets, 888 San Clemente Drive,Newport Beach, CA 92660, (800) 678-9147, rothecm@roth.com, or by accessing the SEC's website at www.sec.gov. Before investing in the offering, interested parties should read in their entirety the prospectus supplement and the accompanying prospectus and the other documents that the company has filed with the SEC that are incorporated by reference in the prospectus supplement and the accompanying prospectus, which provide more information about the company and the offering.This press release shall not constitute an offer to sell, or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation, or sale would be unlawful prior to registration or qualification under thesecurities laws of any such state or jurisdiction.
I'll second that!
unexpected but sounds calculated-
-we'll drop the share price in the short term- everyone on this board will guess by how much, others, namely the nutjobs on this board, will say the sky is falling- but it really doesn't mean anything until they publish the specifics.
- having a bank have a stake in the offering will encourage the bank to promote investment to better their position-
- we will be promoting the co through conferences- again, to entice investment
- with all of this past and expected growth in the future, this is a means to an end.
I would be worried if we were trying to stay afloat akin to bpax, but we are not bpax- we're in a growth phase- I think this is a healthy approach to stimulate more growth through r/d and production as well as enticing new investors.
just my two cents
-RG
Very commonly prescribed drugs, which is GREAT! Should provide a high and steady revenue stream. My only worry was the aquired drugs were small volume prescriptions that Teva wanted to get rid of, this is absolutely not the case! Great news! Thanks again JTFM!
-RG
Earnings before the bell 2/18/14.
RG
it's what we already know, but it's good that it's out there.
Contract Manufacturing: Often Ignored, But Potentially Profitable
GTLA
-RG
So you're saying that ALL patients prescribed viagra suffer from hypertension...think about that again.
Also, you may want to delete your browser history, having someone discover you were searching for viagra may embarass you even more than from the nonsense found in your posts over the past month.
-RG